We think that MannKind Corporation (MNKD) is one of the best speculations in the market. MannKind has developed a mealtime insulin, Afrezza, that closely mimics a healthy human pancreas. This insulin could be the first-line drug therapy in the treatment of type 2 diabetes, which has reached pandemic levels.
The five most important trends and catalysts for MannKind are:
1) Diabetes is the Greatest Challenge Facing the World Today...
- Diabetes is a Pandemic in Full Motion - There are nearly 400 million people in the world with diabetes.
- Diabetes is the Fastest Growing Disease in the World - By 2050, the CDC projects 20-33% of Americans will be diabetic.
- More People Have Prediabetes Than Diabetes